Sirnaomics-B (02257.HK): First Patient Dosed in Phase 2 Clinical Trial of STP705 for Medical Aesthetics

NewTimeSpace News: Sirnaomics Ltd. (02257.HK) issued a voluntary announcement on July 30, 2026, disclosing that the first patient has been successfully dosed in a Phase 2 multicenter clinical trial evaluating STP705 for medical aesthetics.

STP705 leverages the Group's proprietary PNP (Polypeptide Nanoparticle) oligonucleotide delivery platform, enabling site-specific gene regulation to drive controlled adipocyte clearance, thereby offering a minimally invasive treatment alternative to conventional fat reduction therapies. The primary endpoint of this Phase 2 multicenter trial is to systematically evaluate the clinical efficacy of STP705 in achieving targeted subcutaneous fat reduction through local administration, complemented by rigorous secondary assessments encompassing safety, tolerability, and local treatment response characteristics.

The Company stated that this achievement represents a significant clinical milestone for the Group's global RNA therapeutics medical aesthetics pipeline. The clinical readout data generated from this Phase 2 program will support the global development trajectory of the Group's medical aesthetics assets and further reinforce Sirnaomics' leading market position in extra-hepatic siRNA delivery modalities.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.